Trust Board paper U

Directors.

Trust Bourd Paper o									
To: Trust Board									
From:		ACTING DIRECTOR OF FINANCE							
Date:		31 July 2014							
CQC	n .	N/A							
Title:	· · · · · · · · · · · · · · · · · · ·								
Framework Author/Responsible Director: INTERIM DIRECTOR OF FINANCIAL STRATEGY									
Author	Author/nesponsible birector. INTENTINI DINECTOR OF FINANCIAL STRATEGY								
Purpos	e of th	e Report: To	seek app	proval of the Orthopaedic Trauma CMF Implants	3				
and Ass	ociate	d Products Fra	mework						
The De	!		0						
The Re	port is	provided to the	ne Comn	mittee for:					
	Deci	ision	\checkmark	Discussion					
	Deci	131011	ľ						
	٨٥٥١١	rance		Endorsement					
	Assu	ianc e		Endorsement					
Summa	ry / Ke	ey Points: This	decision	n will allow for the award of a Orthopaedic Traum	а				
				cts Framework covering UHL's entire network. Th	is				
				ture contracts in an agile manner in the future,					
including	g subs	equent to mini-	competiti	tions.					
Recom	mands	tione:							
			aedic Tra	rauma CMF Implants and Associated Products					
		work Contract		adma om impanto ana ricconatoa i roddote					
2. T	o dele	gate the author	ity to an	Executive Director to award contracts within the					
				mpetition without the requirement for this to be					
6	approv	ed by Trust Bo	ard.						
Droviou	oly oc	poidored et er	anthor of	corporate UHL Committee?					
Previou	isiy co	insidered at ai	iother co	corporate One Committee?					
Strateg	ic Risl	Register: N/	A	Performance KPIs year to date: N/A All KPI's	 S				
			will be specified within the mini-competitions						
				under the framework.					
Resource Implications (e.g. Financial, HR): None									
Assurance Implications: N/A									
Patient and Public Involvement (PPI) Implications: N/A									
Stakeholder Engagement Implications: N/A									
Equality	y Impa	ict: N/A - Good	ds						
	-								
Information exempt from Disclosure: N/A									
Requirement for further review? None - Delegated responsibility to the Executive									

1. Project Outline

The Musculoskeletal theatres total spend for the supply of Orthopaedic, Trauma, Craniomaxillofacial (CMF) and Associated products is £4.34million. Due to this significant spend in this area and compliance with EU procurement requirements the CMG initiated a formal tender process to ensure the most cost and clinically effective products were available.

Elective orthopaedics during 2013/14 delivered joint replacements as shown below generating a total income of £25 million. The cost of prostheses in undertaking these procedures was £2.78

million.

Procedure			Activity 13/14
Primary	Total	Hip	
Replacemen	nt		913
Revision	Total	Hip	
Replacemen	nt	-	112
Primary	Total	Knee	
Replacemen	nt		1090
Revision	Total	Knee	
Replacemen	nt		65
Arthroscopy			716

Trauma treated 3257 patients in 2013/14 and is forecast to treat 3445 patients in 2014/15 and generates a total income of c. £12.7million.

It was the intention of this exercise to let a framework agreement to a range of suppliers in order to ensure that the best products are available for patient use and to ensure on-going competition.

A framework agreement does not commit the Trust to purchase product, each individual order creates a contract. Therefore use of a Framework provides maximum flexibility in product selection and market share to generate competition amongst suppliers. This will enable cost control throughout the lifetime of the contract using a number of purchasing techniques catered for in the framework such as bulk purchase and use of market share to achieve best price banding. Other contracting solutions would not provide such flexibility.

The framework agreement will be awarded for three years, with prices fixed for two years, and an option to extend for a further one year.

The contract was advertised in the European journal in January 2014 as an open procedure, for two lots; Lot 1 Orthopaedic Trauma CMF Implants; Lot 2 Tools and Consumables received 57 expressions of interest were received, from which 35 tenders were returned (15 for Lots 1 & 2; 12 For Lot 1 only; 8 for Lot 2 only)

This recommendation concerns Lot 1 only.

2. Scoring & Award

The evaluation criteria used for the evaluation were as follows:

Quality (60%)						
Capabilities (39%)						
Clinical (21%)						
Commercial (40%)						
Cost (30%)						
Added Value (10%)						

An evaluation team was put together comprising Orthopaedic and Musculoskeletal Surgeons, Theatre Staff, CMG Management, Procurement and Finance. Each of the submissions was scored, by section, according to the above criteria by members of the evaluation team.

It had been agreed that tenderers with an acceptable clinical score and an overall score in excess of 50% would be admitted to the framework agreement. The proposed suppliers to be admitted to the framework Agreement are:

Acumed Ltd Arthrex ArthroCare UK B Braun Medical Ltd Biomet UK Ltd Conmed Linvatec DePuy International ltd Exactech (UK) Ltd Joint Replacement Instrumentation Ltd Karl Storz Endoscopy (UK) Ltd MicroPort Orthopaedics Ltd Smith and Nephew Orthopaedics Stryker UK Ltd Xy Xpert Lima Orthopaedics Zimmer Ltd Xy Xy Xy Xy Xy Xy Xy Xy Xy X	Section	Hips	Knees	Trauma lower limb	Trauma upper limb	Spine	Hands	Shoulders	External Fixation	Arthroscopy	CMF
ArthroCare UK B Braun Medical Ltd Biomet UK Ltd Conmed Linvatec DePuy International Itd DP Medical Systems Ltd Exactech (UK) Ltd Joint Replacement Instrumentation Ltd Karl Storz Endoscopy (UK) Ltd Medartis Ltd MicroPort Orthopaedics Ltd Smith and Nephew Orthopaedics Stryker UK Ltd X Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Acumed Ltd				~		~				
B Braun Medical Ltd Biomet UK Ltd Conmed Linvatec DePuy International Itd V V V V V V V V V V V V V V V V V V V	Arthrex		~								
Biomet UK Ltd Conmed Linvatec DePuy International Itd V V V V V V V V V V V V V V V V V V V	ArthroCare UK									~	
Conmed Linvatec DePuy International Itd DP Medical Systems Ltd Exactech (UK) Ltd Joint Replacement Instrumentation Ltd Karl Storz Endoscopy (UK) Ltd Medartis Ltd MicroPort Orthopaedics Ltd Smith and Nephew Orthopaedics Stryker UK Ltd Xpert Lima Orthopaedics	B Braun Medical Ltd	~	~	~							
DePuy International Itd DP Medical Systems Ltd Exactech (UK) Ltd Joint Replacement Instrumentation Ltd Karl Storz Endoscopy (UK) Ltd Medartis Ltd MicroPort Orthopaedics Ltd Smith and Nephew Orthopaedics Stryker UK Ltd Xpert Lima Orthopaedics	Biomet UK Ltd	~	~	~	~	~	~	~			~
DP Medical Systems Ltd Exactech (UK) Ltd Joint Replacement Instrumentation Ltd Karl Storz Endoscopy (UK) Ltd Medartis Ltd MicroPort Orthopaedics Ltd Smith and Nephew Orthopaedics Stryker UK Ltd Xpert Lima Orthopaedics	Conmed Linvatec										~
Exactech (UK) Ltd Joint Replacement Instrumentation Ltd Karl Storz Endoscopy (UK) Ltd Medartis Ltd MicroPort Orthopaedics Ltd Smith and Nephew Orthopaedics Stryker UK Ltd Xpert Lima Orthopaedics		~	~	~	~	~	~	~		~	~
Joint Replacement Instrumentation Ltd Karl Storz Endoscopy (UK) Ltd Medartis Ltd MicroPort Orthopaedics Ltd Smith and Nephew Orthopaedics Stryker UK Ltd Xpert Lima Orthopaedics	DP Medical Systems Ltd					~					
Instrumentation Ltd Karl Storz Endoscopy (UK) Ltd Medartis Ltd MicroPort Orthopaedics Ltd Smith and Nephew Orthopaedics Stryker UK Ltd Xpert Lima Orthopaedics			~		~			~			
Ltd Medartis Ltd MicroPort Orthopaedics Ltd Smith and Orthopaedics Stryker UK Ltd Xpert Lima Orthopaedics		~	~	~							
MicroPort Orthopaedics Ltd Smith and Nephew V V V V V V Orthopaedics Stryker UK Ltd V V V V V V V V V Xpert Lima Orthopaedics			~								
Ltd Smith and Nephew Orthopaedics Stryker UK Ltd Xpert Lima Orthopaedics	Medartis Ltd				~		~				
Orthopaedics Stryker UK Ltd Xpert Lima Orthopaedics			~	~							
Stryker UK Ltd	·	~	~	~	~				~	~	
Xpert Lima Orthopaedics ✓		~	~	~	~	~	~	~			~
		~									
	Zimmer Ltd	~	~	~	~			~	~		

This framework will cover UHL's entire Orthopaedic Trauma CMF Implants, covering an annual spend of c. £4m.

3. Financials

Award of this framework will have a saving of £142,226, as part year effect for 2014/15 and netting the fee payable to Accenture of £197,621. The full year effect savings to be realised for 2015/16 are £718,624 for FY15/16 – any future call-offs from this framework will be made with consideration to improving UHL's financial contribution.

4. Recommendati on & Benefits of Decision

4.1: Recommendations:

Based on the above, on behalf of the project steering group, I make the following recommendations to the board:

Award all 17 eligible suppliers Acumed Ltd Arthrex ArthroCare UK B Braun Medical Ltd Biomet UK Ltd Conmed Linvatec DePuy International Itd DP Medical Systems Ltd Exactech (UK) Ltd Joint Replacement Instrumentation Ltd Karl Storz Endoscopy (UK) Ltd Medartis Ltd MicroPort Orthopaedics Ltd Smith and Nephew Orthopaedics Strvker UK Ltd **Xpert Lima Orthopaedics** Zimmer Ltd

to UHL's new procurement Framework.

To delegate the authority to an Executive Director to award contracts within the framework following any mini-competition without the requirement for this to be approved by Trust Board.

4.2: Benefits of Decision:

Award of this framework will have the following benefits to UHL:

Responsive Award of Prosthesis Call-Offs:

 A framework agreement does not commit the Trust to purchase product, each individual order creates a contract. Therefore use of a Framework provides maximum flexibility in product selection and market share to generate competition amongst suppliers. This will enable cost control throughout the lifetime of the contract using a number of purchasing techniques catered for in the framework such as bulk purchase and use of market share to achieve best price banding. Other contracting solutions would not provide such flexibility

Added Value Schemes

 Each of the companies have offered additional schemes, such as Theatre efficiency programmes, HRG coding guides, enhanced recovery programmes and pathway performance programmes which will allow UHL to reduce costs.

Consignment Stock:

 The main suppliers all offer consignment stocks, (stock wholly owned and managed by the supplier and paid for as used) which will allow UHL to reduce stock costs.

Financial savings are expect to begin to impact after the framework is fully implemented which will take up to eight weeks. This period is required for any new suppliers to place instrumentation and stocks of implants with the Trust.